Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 105, Issue 1, 2007, Pages 59-65

  Modesitt, Susan C ^a   Tian, Chunqiao ^b   Kryscio, Richard ^b   Thigpen, J Tate ^c   Randall, Marcus E ^d   Gallion, Holly H ^e   Fleming, Gini F ^f  

^a UNIVERSITY OF VIRGINIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d Carolina University in Greenville   (United States)

^e Precision Therapeutics Inc   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

Endometrial cancer; Lower uterine segment; Nodal disease; Prognosis

Indexed keywords

CISPLATIN; DOXORUBICIN;

ADULT; AGED; ANEMIA; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MORBID OBESITY; NEUROLOGIC DISEASE; NEUTROPENIA; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; CISPLATIN; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33947320788     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.10.045     Document Type: Article

References (48)

1. Hedley A.A., Ogden C.L., Johnson C.L., Carroll M.D., Curtin L.R., and Flegal K.M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291 (2004) 2847-2850
2. James P.T. Obesity: the worldwide epidemic. Clin. Dermatol. 22 (2004) 276-280
3. Vaino H., and Bianchini F. IARC Handbooks of cancer prevention, volume 6, weight control and physical activity. 1st ed. (2002), International Agency for Research on Cancer, Lyon, France
4. Akhmedkhanov A., Zeleniuch-Jacquotte A., and Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann. N. Y. Acad. Sci. 943 (2001) 296-315
5. Albanes D. Caloric intake, body weight, and cancer: a review. Nutr. Cancer 9 (1987) 199-217
6. Austin H., Austin Jr. J.M., Partridge E.E., Hatch K.D., and Shingleton H.M. Endometrial cancer, obesity, and body fat distribution. Cancer Res. 51 (1991) 568-572
7. Bergstrom A., Pisani P., Tenet V., Wolk A., and Adami H.O. Overweight as an avoidable cause of cancer in Europe. Int. J. Cancer 91 (2001) 421-430
8. Blitzer P.H., Blitzer E.C., and Rimm A.A. Association between teen-age obesity and cancer in 56, 111 women: all cancers and endometrial carcinoma. Prev. Med. 5 (1976) 20-31
9. Brinton L.A., Berman M.L., Mortel R., Twiggs L.B., Barrett R.J., Wilbanks G.D., et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am. J. Obstet. Gynecol. 167 (1992) 1317-1325
10. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348 (2003) 1625-1638
11. Carroll K.K. Obesity as a risk factor for certain types of cancer. Lipids 33 (1998) 1055-1059
12. Gangemi M., Meneghetti G., Predebon O., Scappatura R., and Rocco A. Obesity as a risk factor for endometrial cancer. Clin. Exp. Obstet. Gynecol. 14 (1987) 119-122
13. Jonsson F., Wolk A., Pedersen N.L., Lichtenstein P., Terry P., Ahlbom A., et al. Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish Twin Registry. Int. J. Cancer 106 (2003) 594-599
14. Kaaks R., Lukanova A., and Kurzer M.S. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 1531-1543
15. Lapidus L., Helgesson O., Merck C., and Bjorntorp P. Adipose tissue distribution and female carcinomas. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Int. J. Obes. 12 (1988) 361-368
16. Le Marchand L., Wilkens L.R., and Mi M.P. Early-age body size, adult weight gain and endometrial cancer risk. Int. J. Cancer 48 (1991) 807-811
17. Levi F., La Vecchia C., Negri E., Parazzini F., and Franceschi S. Body mass at different ages and subsequent endometrial cancer risk. Int. J. Cancer 50 (1992) 567-571
18. Olson S.H., Trevisan M., Marshall J.R., Graham S., Zielezny M., Vena J.E., et al. Body mass index, weight gain, and risk of endometrial cancer. Nutr. Cancer 23 (1995) 141-149
19. Parazzini F., Negri E., La Vecchia C., Bruzzi P., and Decarli A. Population attributable risk for endometrial cancer in northern Italy. Eur. J. Cancer Clin. Oncol. 25 (1989) 1451-1456
20. Petridou E., Belechri M., Dessypris N., Koukoulomatis P., Diakomanolis E., Spanos E., et al. Leptin and body mass index in relation to endometrial cancer risk. Ann. Nutr. Metab. 46 (2002) 147-151
21. Salazar-Martinez E., Lazcano-Ponce E.C., Lira-Lira G.G., Escudero-De los Rios P., Salmeron-Castro J., Larrea F., et al. Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control 11 (2000) 707-711
22. Shoff S.M., and Newcomb P.A. Diabetes, body size, and risk of endometrial cancer. Am. J. Epidemiol. 148 (1998) 234-240
23. Swanson C.A., Potischman N., Wilbanks G.D., Twiggs L.B., Mortel R., Berman M.L., et al. Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol. Biomarkers Prev. 2 (1993) 321-327
24. Tornberg S.A., and Carstensen J.M. Relationship between Quetelet's index and cancer of breast and female genital tract in 47,000 women followed for 25 years. Br. J. Cancer 69 (1994) 358-361
25. Weiderpass E., Persson I., Adami H.O., Magnusson C., Lindgren A., and Baron J.A. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 11 (2000) 185-192
26. Wolk A., Gridley G., Svensson M., Nyren O., McLaughlin J.K., Fraumeni J.F., et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12 (2001) 13-21
27. Xu W., Dai Q., Ruan Z., Cheng J., Jin F., and Shu X. Obesity at different ages and endometrial cancer risk factors in urban Shanghai, China. Zhonghua Liu Xing Bing Xue Za Zhi 23 (2002) 347-351
28. Modesitt S.C., and van Nagell Jr. J.R. The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet. Gynecol. Surv. 60 (2005) 683-692
29. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics. CA Cancer J. Clin. 56 (2006) 106-130
30. Meyerhardt J.A., Tepper J.E., Niedzwiecki D., Hollis D.R., McCollum A.D., Brady D., et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J. Clin. Oncol. 22 (2004) 648-657
31. Bastarrachea J., Hortobagyi G.N., Smith T.L., Kau S.W., and Buzdar A.U. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann. Intern. Med. 120 (1994) 18-25
32. Berclaz G., Li S., Price K.N., Coates A.S., Castiglione-Gertsch M., Rudenstam C.M., et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann. Oncol. 15 (2004) 875-884
33. Meyerhardt J.A., Catalano P.J., Haller D.G., Mayer R.J., Benson III A.B., Macdonald J.S., et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98 (2003) 484-495
34. Rosner G.L., Hargis J.B., Hollis D.R., Budman D.R., Weiss R.B., Henderson I.C., et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J. Clin. Oncol. 14 (1996) 3000-3008
35. Georgiadis M.S., Steinberg S.M., Hankins L.A., Ihde D.C., and Johnson B.E. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J. Natl. Cancer Inst. 87 (1995) 361-366
36. Colleoni M., Li S., Gelber R.D., Price K.N., Coates A.S., Castiglione-Gertsch M., et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 366 (2005) 1108-1110
37. Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., Vaccarello L., et al. Phase III randomized trial of doxorubicin+ cisplatin versus doxorubicin+ 24-h paclitaxel+ filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann. Oncol. 15 (2004) 1173-1178
38. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 22 (2004) 2159-2166
39. Gallion H.H., Brunetto V.L., Cibull M., Lentz S.S., Reid G., Soper J.T., et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 21 (2003) 3808-3813
40. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 22 (2004) 3902-3908
41. Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler J., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 24 (2006) 36-44
42. De Jonge M.E., Mathot R.A., Van Dam S.M., Beijnen J.H., and Rodenhuis S. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother. Pharmacol. 50 (2002) 251-255
43. Joerger M., Huitema A.D.R., van den Bongard D.H.J.G., Schellens J.H.M., and Beijnen J.H. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. Clin. Cancer Res. 12 (2006) 2150-2157 [%R 10.1158/1078-0432.CCR-05-2069]
44. Loos W.J., de Jongh F.E., Sparreboom A., de Wit R., van Boven-van Zomeren D.M., Stoter G., et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J. Clin. Oncol. 24 (2006) 1499-1506 [%R 10.1200/JCO.2005.03.0056]
45. Humber C., Tierney J., Symonds P., Collingwood M., Kirwan J., Williams C., et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst. Rev. (2005) CD003915
46. Gurney H. Developing a new framework for dose calculation. J. Clin. Oncol. 24 (2006) 1489-1490 [%R 10.1200/JCO.2005.05.1607]
47. Chlebowski R.T., Aiello E., and McTiernan A. Weight loss in breast cancer patient management. J. Clin. Oncol. 20 (2002) 1128-1143
48. Rock C.L., and Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J. Clin. Oncol. 20 (2002) 3302-3316